QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer
This is a single-center, open-label, exploratory study aims to assess the efficacy and safety of QL1706 plus nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma.
Metastatic Pancreatic Cancer
DRUG: QL1706|DRUG: Chidamide|DRUG: Gemcitabine|DRUG: Nab-paclitaxel
ORR, overall response rate, 1 year
OS, OS is defined as the time from date of treatment start to the date of death from any cause or to the date of last follow-up if patients are alive. If a patient is alive by the time of final analysis, the patient will be censored at the last follow-up date., 2 year|AEs, Defined as the proportion of patients with AE, treatment-related AE (TRAE), immune-related AE (irAE), serious adverse event (SAE), assessed by NCI CTCAE v5.0, 2 year|Progression-free Survival (PFS), PFS was assessed by investigators per RECIST 1.1, 2 year|Disease Control Rate (DCR), DCR was assessed by investigators per RECIST 1.1, 2 year|Duration of Response (DOR), DOR was assessed by investigators per RECIST 1.1, 2 year
This is a single-center, open-label, exploratory study aims to assess the efficacy and safety of QL1706 plus nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma.